Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Advanced Cancer
Interventions: Psilocybin 25 mgs, Niacin 100mg, Psychotherapy; Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Patients Susceptible to Falls
Interventions: Not listed
Lead sponsor: Curbell Medical Products, Inc.; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Cheektowaga, New York

Conditions: Second Hand Tobacco Smoke
Interventions: Smoke-free homes intervention; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: KSI-301; Drug
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 21 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more

Conditions: HIV, Hepatitis C, Hepatitis B, Syphilis
Interventions: Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis, HIV only; Device
Lead sponsor: California State University, Long Beach; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Surgical Site Infection, Sternal Infection, Cardiac Surgery
Interventions: D-PLEX, Standard of Care; Drug · Other
Lead sponsor: PolyPid Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Rochester, Minnesota • Huston, Texas

Conditions: Renal Impairment
Interventions: Lorcaserin 10mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Interventions: PF-07921585, Sasanlimab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more

Conditions: Multimodal Analgesia, Nonsteroidal Anti-inflammatory Drugs
Interventions: Ibuprofen 600 mg, standard oxycodone/acetaminophen; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Sudden Cardiac Death, Arrhythmias, Congestive Heart Failure, Cardiomyopathy
Interventions: Not listed
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 1,807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • Columbus, Ohio + 1 more

Conditions: HIV, HIV/AIDS, HIV-1 Infection
Interventions: Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074; Drug
Lead sponsor: Luis Montaner; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Dextroamphetamine, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Type 2 Diabetes Mellitus
Interventions: LGD-6972, Placebo (Captisol®); Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Right Heart Catheterization
Interventions: SimpleSense; Device
Lead sponsor: Nanowear Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Advanced Solid Tumors
Interventions: mRNA-4106, Pembrolizumab, mRNA-4200; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • San Antonio, Texas + 1 more

Conditions: Stroke, Spasticity, Muscle
Interventions: Conventional robotic continuous passive movement training, Visual Feedback, Haptic and Visual Feedback; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HPV Vaccination, Uptake Vaccination, Series Completion
Interventions: PREVENT; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hepatic Insufficiency
Interventions: Alisporivir; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Musculoskeletal Pain
Interventions: Acetaminophen, Oxycodone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Breast Cancer Metastases, HER2 Positive Breast
Interventions: 89Zr-trastuzumab, PET/CT scan, 89Zr-pertuzumab; Radiation · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: Emraclidine, Esomeprazole; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Alcohol Use Disorder
Interventions: CMND-100; Drug
Lead sponsor: Clearmind Medicine Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Baltimore, Maryland

Conditions: Covid19
Interventions: sotrovimab, Placebo to Biologic; Biological · Other
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Anaheim, California • Glendale, California

Conditions: Prostate Cancer
Interventions: tasquinimod, tasquinimod 0.25 mg; 0.5 mg, tasquinimod 0.25 mg; 0.5 mg; 1.0 mg; Drug
Lead sponsor: Andrew J. Armstrong, MD; Other
Eligibility: 18 Years to 79 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois • Durham, North Carolina

Search by objective public record fields.

Psilocybin Therapy in Advanced Cancer

A Pilot Study to Assess the Association Between Human Bioimpedance Measurements and Clinical Urodynamic Procedures

Implementing a Scalable Smoke-free Home Intervention in Armenia and Georgia

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Behavioral Science Aspects of Rapid Test Acceptance

D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

NSAID vs. Narcotics

Genetic Risk Assessment of Defibrillator Events

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

The Nanowear Wearable System SimpleSense Validation Trial for Cardiac Output

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

Robotic Interventions for Spasticity Treatment

PREVENT Pilot HPV - Related Cancers Trial

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

Acetaminophen (APAP) +/- Oxycodone

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer